Home » Newsletters » BioWorld

BioWorld

Oct. 4, 2000

View Archived Issues

Syrrx Raises $20M In 2nd Round To Advance Structural Genomics

Trimeris, Roche Move Fusion Inhibitor Into Phase III Studies

Other News To Note

Ill-Fated New Drug Study Aimed At Autoimmune Root of Multiple Sclerosis Netted Some Lessons

Informax IPO Garners $80M For Bioinformatics Platform

Affymetrix Forms $100M Firm Expected To Read 50 Genomes

Today's news in brief
BioWorld
BioWorld briefs for Jan. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 17, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Abbvie and Simcere enter a $1B T-cell engager deal
BioWorld Asia
Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the 43rd annual J.P. Morgan Healthcare...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.